相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma
Lin Lin et al.
CANCER RESEARCH AND TREATMENT (2021)
Clinical features associated with the efficacy of chemotherapy in patients with glioblastoma (GBM): a surveillance, epidemiology, and end results (SEER) analysis
Jieqiong Wen et al.
BMC CANCER (2021)
MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review
Sebastian Brandner et al.
NEURO-ONCOLOGY (2021)
Effect of valproic acid on overall survival in patients with high-grade gliomas undergoing temozolomide A nationwide population-based cohort study in Taiwan
Yu-Jen Kuo et al.
MEDICINE (2020)
Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?
Yang He et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide
Iris Maria Forte et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2019)
Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas
Lawrence A. Donehower et al.
CELL REPORTS (2019)
Valproic acid treatment response in vitro is determined by TP53 status in medulloblastoma
Bruna Mascaro-Cordeiro et al.
CHILDS NERVOUS SYSTEM (2018)
The Clinical Significance of O6-Methylguanine-DNA Methyltransferase Promoter Methylation Status in Adult Patients With Glioblastoma: A Meta-analysis
Yu-Hang Zhao et al.
FRONTIERS IN NEUROLOGY (2018)
The survival effect of valproic acid in glioblastoma and its current trend: a systematic review and meta-analysis
Victor M. Lu et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2018)
Valproic acid attenuates immunosuppressive function of myeloid-derived suppressor cells
Zhiqi Xie et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2018)
Recurrent Glioblastomas Exhibit Higher Expression of Biomarkers with Stem-like Properties
B. N. Nandeesh et al.
JOURNAL OF NEUROSCIENCES IN RURAL PRACTICE (2018)
Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma
Shinichi Watanabe et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma
Peter Campbell et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2017)
Prophylactic anticonvulsants in patients with primary glioblastoma
Arvin R. Wali et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas
Leiming Wang et al.
PATHOLOGY RESEARCH AND PRACTICE (2017)
Valproic acid inhibits glioblastoma multiforme cell growth via paraoxonase 2 expression
Jen-Ho Tseng et al.
ONCOTARGET (2017)
Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives
Wojciech Szopa et al.
BIOMED RESEARCH INTERNATIONAL (2017)
Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair
Yanxin Lu et al.
CANCER RESEARCH (2017)
Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010
Chaturia Rouse et al.
NEURO-ONCOLOGY (2016)
Prognostic relevance of epilepsy at presentation in glioblastoma patients
Sharon Berendsen et al.
NEURO-ONCOLOGY (2016)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
Roles of Valproic Acid in Improving Radiation Therapy for Glioblastoma: a Review of Literature Focusing on Clinical Evidence
Satoru Ochiai et al.
Asian Pacific Journal of Cancer Prevention (2016)
Silencing of histone deacetylase 2 suppresses malignancy for proliferation, migration, and invasion of glioblastoma cells and enhances temozolomide sensitivity
Zhiqiang Zhang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data
Liacine Bouaoun et al.
HUMAN MUTATION (2016)
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2016)
Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia
Calum Leitch et al.
ONCOTARGET (2016)
Temozolomide resistance in glioblastoma multiforme
Sang Y. Lee
GENES & DISEASES (2016)
Valproic Acid Induces the Hyperacetylation of P53, Expression of P53 Target Genes, and Markers of the Intrinsic Apoptotic Pathway in Midorganogenesis Murine Limbs
France-Helene Paradis et al.
BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY (2015)
Actin cytoskeleton organization, cell surface modification and invasion rate of 5 glioblastoma cell lines differing in PTEN and p53 status
Cholpon S. Djuzenova et al.
EXPERIMENTAL CELL RESEARCH (2015)
The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells
Abdel Nasser Hosein et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis
Wang Miao et al.
MOLECULAR MEDICINE REPORTS (2015)
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors
Jeanette E. Eckel-Passow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The Evidence of Glioblastoma Heterogeneity
Akio Soeda et al.
SCIENTIFIC REPORTS (2015)
Panobinostat for the treatment of multiple myeloma: the evidence to date
Hanna Bailey et al.
JOURNAL OF BLOOD MEDICINE (2015)
Survival analysis for valproic acid use in adult glioblastoma multiforme: A meta-analysis of individual patient data and a systematic review
Yang Yuan et al.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2014)
Unravelling mechanisms of p53-mediated tumour suppression
Kathryn T. Bieging et al.
NATURE REVIEWS CANCER (2014)
The Somatic Genomic Landscape of Glioblastoma
Cameron W. Brennan et al.
CELL (2013)
IDH1 and IDH2 Mutations in Gliomas
Adam L. Cohen et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2013)
A prospective randomized trial of perioperative seizure prophylaxis in patients with intraparenchymal brain tumors Clinical article
Adam S. Wu et al.
JOURNAL OF NEUROSURGERY (2013)
Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme
Melissa Kerkhof et al.
NEURO-ONCOLOGY (2013)
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas
P. Wang et al.
ONCOGENE (2013)
Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics
Andrea Sottoriva et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme
Bryant England et al.
TUMOR BIOLOGY (2013)
IDH1 mutation is associated with improved overall survival in patients with glioblastoma: a meta-analysis
Hong-Bin Cheng et al.
TUMOR BIOLOGY (2013)
O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas
C-H Fan et al.
CELL DEATH & DISEASE (2013)
Effect of valproic acid on the outcome of glioblastoma multiforme
Hong-Chieh Tsai et al.
BRITISH JOURNAL OF NEUROSURGERY (2012)
Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed
Berkley E. Gryder et al.
FUTURE MEDICINAL CHEMISTRY (2012)
Valproic Acid Downregulates the Expression of MGMT and Sensitizes Temozolomide-Resistant Glioma Cells
Chung Heon Ryu et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2012)
Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients
Sameer Agnihotri et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia
E. McCormack et al.
LEUKEMIA (2012)
Intrinsic Anticancer Drug Resistance of Malignant Melanoma Cells Is Abrogated by IFN-β and Valproic Acid
Wynand P. Roos et al.
CANCER RESEARCH (2011)
Enhancement of temozolomide-induced apoptosis by valproic acid in human glioma cell lines through redox regulation
Ching-Hsein Chen et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2011)
Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?
Nanne K. Kloosterhof et al.
LANCET ONCOLOGY (2011)
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Roel G. W. Verhaak et al.
CANCER CELL (2010)
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Michael Weller et al.
NATURE REVIEWS NEUROLOGY (2010)
MGMT promoter methylation in malignant gliomas
Markus J. Riemenschneider et al.
TARGETED ONCOLOGY (2010)
HDAC Inhibitor, Valproic Acid, Induces p53-Dependent Radiosensitization of Colon Cancer Cells
Xufeng Chen et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2009)
The Neuropharmacokinetics of Temozolomide in Patients with Resectable Brain Tumors: Potential Implications for the Current Approach to Chemoradiation
Jana Portnow et al.
CLINICAL CANCER RESEARCH (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
p53 and E2f: partners in life and death
Shirley Polager et al.
NATURE REVIEWS CANCER (2009)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
PUMA, a potent killer with or without p53
J. Yu et al.
ONCOGENE (2008)
MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome
Dorothee Wiewrodt et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
The 2007 WHO classification of tumours of the central nervous system
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2007)
Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O-6-methylguanine
W. P. Roos et al.
ONCOGENE (2007)
Therapeutic efficacy of PUMA for malignant glioma cells regardless of p53 status
H Ito et al.
HUMAN GENE THERAPY (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Prognostic factors for survival of patients with glioblastoma: Recursive partitioning analysis
KR Lamborn et al.
NEURO-ONCOLOGY (2004)
Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients
S Ostermann et al.
CLINICAL CANCER RESEARCH (2004)
The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2
OH Krämer et al.
EMBO JOURNAL (2003)
p53, mdm2, EGFR, and msh2 expression in paired initial and recurrent glioblastoma multiforme
AM Stark et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2003)
PUMA, a novel proapoptotic gene, is induced by p53
K Nakano et al.
MOLECULAR CELL (2001)
分享论文
